DDI2

Summary

DDI2 (DDI proteasomal shuttling factor 2, HGNC:24578) is a protein-coding gene on chromosome 1p36.21, encoding Protein DDI1 homolog 2 (Q5TDH0). Aspartic protease that mediates the cleavage of NFE2L1/NRF1 at ‘Leu-104’, thereby promoting release of NFE2L1/NRF1 from the endoplasmic reticulum membrane.

Enables aspartic-type endopeptidase activity; identical protein binding activity; and ubiquitin binding activity. Involved in several processes, including cellular response to hydroxyurea; proteolysis; and regulation of DNA stability. Located in cytosol and nucleoplasm.

Source: NCBI Gene 84301 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 133 total — 1 pathogenic
• MANE Select transcript: NM_032341

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24578
Approved symbol	DDI2
Name	DDI proteasomal shuttling factor 2
Location	1p36.21
Locus type	gene with protein product
Status	Approved
Aliases	MGC14844
Ensembl gene	ENSG00000197312
Ensembl biotype	protein_coding
OMIM	620871
Entrez	84301

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 3 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000320153, ENST00000480945, ENST00000483899, ENST00000486680, ENST00000546927, ENST00000548451, ENST00000711098, ENST00000711099

RefSeq mRNA: 1 — MANE Select: NM_032341 NM_032341

CCDS: CCDS30607

Canonical transcript exons

ENST00000480945 — 10 exons

Exon	Start	End
ENSE00001351972	15638307	15638434
ENSE00001368705	15633439	15633565
ENSE00001925600	15617458	15617808
ENSE00003566844	15643522	15643650
ENSE00003584951	15630325	15630561
ENSE00003648620	15649720	15649823
ENSE00003690124	15626669	15626798
ENSE00003690768	15651706	15651895
ENSE00004014538	15659837	15669044
ENSE00004014540	15656617	15656679

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 97.33.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.0789 / max 161.3156, expressed in 1804 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
886	16.2476	1795
888	2.8579	1398
885	1.1892	731
887	0.4182	212
889	0.3659	155

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibialis anterior	UBERON:0001385	97.33	gold quality
deltoid	UBERON:0001476	96.57	gold quality
upper arm skin	UBERON:0004263	95.76	gold quality
palpebral conjunctiva	UBERON:0001812	95.05	gold quality
esophagus squamous epithelium	UBERON:0006920	94.66	gold quality
quadriceps femoris	UBERON:0001377	94.55	gold quality
vastus lateralis	UBERON:0001379	94.44	gold quality
sural nerve	UBERON:0015488	94.22	gold quality
trabecular bone tissue	UBERON:0002483	94.18	gold quality
oviduct epithelium	UBERON:0004804	93.70	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	93.62	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	93.48	gold quality
ileal mucosa	UBERON:0000331	93.47	gold quality
oral cavity	UBERON:0000167	93.09	gold quality
biceps brachii	UBERON:0001507	93.02	gold quality
skeletal muscle tissue	UBERON:0001134	92.83	gold quality
kidney epithelium	UBERON:0004819	91.74	gold quality
jejunal mucosa	UBERON:0000399	91.53	gold quality
nasal cavity epithelium	UBERON:0005384	91.44	gold quality
bronchial epithelial cell	CL:0002328	91.18	gold quality
epithelial cell of pancreas	CL:0000083	91.09	gold quality
muscle tissue	UBERON:0002385	90.79	gold quality
bronchus	UBERON:0002185	90.75	gold quality
skin of hip	UBERON:0001554	89.55	gold quality
liver	UBERON:0002107	89.54	gold quality
upper leg skin	UBERON:0004262	89.54	gold quality
corpus epididymis	UBERON:0004359	89.43	gold quality
pigmented layer of retina	UBERON:0001782	89.32	gold quality
jejunum	UBERON:0002115	89.17	gold quality
mucosa of sigmoid colon	UBERON:0004993	88.65	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.91
E-MTAB-9689	no	148.66

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

114 targeting DDI2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248

Literature-anchored findings (GeneRIF, showing 6)

• the 3D structures of the human Ddi2 UBL and RVP domains were solved and identified a new helical domain that extends on either side of the Rretroviral protease-like dimer. (PMID:27461074)
• Here the authors show that the aspartyl protease DNA-damage inducible 1 homolog 2 (DDI2) is required to cleave and activate Nrf1. (PMID:27528193)
• DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1. (PMID:32521225)
• Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival. (PMID:34649278)
• The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma. (PMID:35589686)
• UBE4A catalyzes NRF1 ubiquitination and facilitates DDI2-mediated NRF1 cleavage. (PMID:37084817)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ddi2	ENSDARG00000006477
drosophila_melanogaster	rngo	FBGN0030753
caenorhabditis_elegans		WBGENE00015308

Paralogs (4): NRIP2 (ENSG00000053702), UBAC2 (ENSG00000134882), DDI1 (ENSG00000170967), NRIP3 (ENSG00000175352)

Protein

Protein identifiers

Protein DDI1 homolog 2 — Q5TDH0 (reviewed: Q5TDH0)

All UniProt accessions (5): A0AA34QVL7, A0AA34QVV2, H0YI90, H0YII4, Q5TDH0

UniProt curated annotations — full annotation on UniProt →

Function. Aspartic protease that mediates the cleavage of NFE2L1/NRF1 at ‘Leu-104’, thereby promoting release of NFE2L1/NRF1 from the endoplasmic reticulum membrane. Ubiquitination of NFE2L1/NRF1 is a prerequisite for cleavage, suggesting that DDI2 specifically recognizes and binds ubiquitinated NFE2L1/NRF1. Seems to act as a proteasomal shuttle which links the proteasome and replication fork proteins like RTF2. Required, with DDI1, for cellular survival following replication stress. Together or redudantly with DDI1, removes RTF2 from stalled forks to allow cell cycle progression after replication stress and maintains genome integrity.

Subunit / interactions. Homodimer. Interacts with MCM6; PCNA; PSMD4; PSMD8; RPA2 and RPN2. Interacts with RTF2.

Subcellular location. Cytoplasm. Cytosol. Chromosome.

Similarity. Belongs to the DDI1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q5TDH0-1	1	yes
Q5TDH0-2	2
Q5TDH0-3	3

RefSeq proteins (1): NP_115717* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000626	Ubiquitin-like_dom	Domain
IPR019103	Peptidase_aspartic_DDI1-type	Domain
IPR021109	Peptidase_aspartic_dom_sf	Homologous_superfamily
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR033882	DDI1_N	Domain
IPR057273	Ddi1/2_HDD	Domain

Pfam: PF00240, PF09668, PF24669

UniProt features (43 total): strand 13, helix 12, modified residue 6, turn 3, splice variant 2, chain 1, domain 1, mutagenesis site 1, region of interest 1, short sequence motif 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
4RGH	X-RAY DIFFRACTION	1.9
2N7D	SOLUTION NMR
5K57	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5TDH0-F1	79.85	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 252

Post-translational modifications (6): 150, 194, 104, 106, 121, 128

Mutagenesis-validated functional residues (1):

Position	Phenotype
252	abolishes aspartic protease activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 242 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_NEGATIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_CARBOHYDRATE_TRANSPORT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT, MORF_RAD51L3, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_GOLGI_TO_PLASMA_MEMBRANE_TRANSPORT, GOBP_PROTEIN_MATURATION, GOBP_NEGATIVE_REGULATION_OF_TRANSPORT

GO Biological Process (6): proteasomal protein catabolic process (GO:0010498), protein processing (GO:0016485), regulation of protein stability (GO:0031647), cellular response to hydroxyurea (GO:0072711), regulation of DNA stability (GO:0097752), proteolysis (GO:0006508)

GO Molecular Function (6): aspartic-type endopeptidase activity (GO:0004190), identical protein binding (GO:0042802), ubiquitin binding (GO:0043130), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (4): nucleoplasm (GO:0005654), chromosome (GO:0005694), cytosol (GO:0005829), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of biological quality	2
protein catabolic process	1
proteolysis	1
protein maturation	1
response to hydroxyurea	1
cellular response to nitrogen compound	1
protein metabolic process	1
endopeptidase activity	1
aspartic-type peptidase activity	1
protein binding	1
ubiquitin-like protein binding	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
nuclear lumen	1
intracellular membraneless organelle	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

758 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DDI2	NGLY1	Q96IV0	722
DDI2	NFE2L1	Q14494	719
DDI2	PSMD2	Q13200	570
DDI2	PSMD4	P55036	568
DDI2	RTF2	Q9BY42	545
DDI2	RAD23A	P54725	524
DDI2	UBQLN1	Q9UMX0	516
DDI2	ADRM1	Q16186	495
DDI2	MAFF	Q9ULX9	494
DDI2	MAFG	O15525	493
DDI2	RAD23B	P54727	489
DDI2	NFE2L3	Q9Y4A8	480
DDI2	MAFK	O60675	480
DDI2	UBQLN2	Q9UHD9	476
DDI2	PSMC4	P43686	469

IntAct

55 interactions, top by confidence:

A	B	Type	Score
ZNF7	IPO8	psi-mi:“MI:0914”(association)	0.530
CPNE2	HIP1	psi-mi:“MI:0914”(association)	0.530
HP1BP3	IPO8	psi-mi:“MI:0914”(association)	0.530
RDH5	NME2P1	psi-mi:“MI:0914”(association)	0.530
ZG16B	ITIH2	psi-mi:“MI:0914”(association)	0.530
ZDHHC1	PIK3CA	psi-mi:“MI:0914”(association)	0.530
CPNE2	DNM1L	psi-mi:“MI:0914”(association)	0.530
UBL4A	DDI2	psi-mi:“MI:0915”(physical association)	0.400
DDI2	LRRC41	psi-mi:“MI:0915”(physical association)	0.400
DDI2	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
MOGAT2	DDI2	psi-mi:“MI:0915”(physical association)	0.400
DDI2	USP47	psi-mi:“MI:0915”(physical association)	0.400
CYP2B6	DDI2	psi-mi:“MI:0915”(physical association)	0.400
JAZF1	TNPO2	psi-mi:“MI:0914”(association)	0.350
SUZ12	TNPO2	psi-mi:“MI:0914”(association)	0.350
ZNF578	IPO8	psi-mi:“MI:0914”(association)	0.350
ZIM3	IPO8	psi-mi:“MI:0914”(association)	0.350
ZNF138	PPM1G	psi-mi:“MI:0914”(association)	0.350
ZNF222	PPM1G	psi-mi:“MI:0914”(association)	0.350
ZNF267	DNAJB6	psi-mi:“MI:0914”(association)	0.350
ZNF419	IPO8	psi-mi:“MI:0914”(association)	0.350
ZNF441	PPP2CB	psi-mi:“MI:0914”(association)	0.350
ZNF480	IPO8	psi-mi:“MI:0914”(association)	0.350
ZNF549	IPO8	psi-mi:“MI:0914”(association)	0.350
ZNF695	PDCD5	psi-mi:“MI:0914”(association)	0.350
ZNF763	CSNK2A2	psi-mi:“MI:0914”(association)	0.350
ZNF846	IPO8	psi-mi:“MI:0914”(association)	0.350
C1QC	C1QL1	psi-mi:“MI:0914”(association)	0.350
RAD23B	UBE4B	psi-mi:“MI:0914”(association)	0.350

BioGRID (148): DDI2 (Affinity Capture-MS), DDI2 (Affinity Capture-MS), CCDC6 (Co-fractionation), COA7 (Co-fractionation), DDI2 (Co-fractionation), HAT1 (Co-fractionation), TLN2 (Co-fractionation), TOM1 (Co-fractionation), TRMT6 (Co-fractionation), TTC4 (Co-fractionation), DDI2 (Affinity Capture-MS), DDI2 (Affinity Capture-MS), DDI2 (Affinity Capture-MS), DDI2 (Affinity Capture-MS), DDI2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8I6G705, A1L3K1, B5DFF2, B5DFI8, G3MWR8, O19048, O19137, O88508, P06730, P29338, P57721, P57722, P60335, Q12800, Q13888, Q15365, Q15366, Q16763, Q1LZ53, Q1RML1, Q28D01, Q2TBV5, Q4W5Z4, Q5E9A3, Q5FVR7, Q5NVP9, Q5TDH0, Q61990, Q6AYU1, Q6DH13, Q6P1K8, Q6ZRY4, Q7RTP6, Q8C6G8, Q8CCI5, Q8CJ19, Q8IY57, Q8N488, Q8VC52, Q921J4

Diamond homologs: A0JPP7, A1CDT9, A1DCU5, A2ADY9, I7HUG0, P0CS14, P0CS15, P40087, Q0CJ13, Q0U3Y6, Q10256, Q17569, Q1DNB9, Q1EBV4, Q2H085, Q2T9Z1, Q2USD7, Q497D6, Q4WGS4, Q54JB0, Q5AY89, Q5TDH0, Q6BK42, Q6CFI3, Q6CNS3, Q6FQE9, Q6TH22, Q754R2, Q7S906, Q7ZYA7, Q8WTU0, Q95JI3, Q9DAF3, Q9BQI9, P0C273, P0C275, P0C276, P0CG82, P0CH10, P0CH11

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

133 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	109
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
584380	NC_000001.10:g.(?15764961)(16063358_?)del	Pathogenic

SpliceAI

1851 predictions. Top by Δscore:

Variant	Effect	Δscore
1:15617804:GCCAG:G	donor_gain	1.0000
1:15617805:CCAGG:C	donor_loss	1.0000
1:15617806:CAGGT:C	donor_loss	1.0000
1:15617809:G:C	donor_loss	1.0000
1:15617810:T:G	donor_loss	1.0000
1:15626666:TAG:T	acceptor_loss	1.0000
1:15626667:A:AC	acceptor_loss	1.0000
1:15626667:A:AG	acceptor_gain	1.0000
1:15626668:G:GT	acceptor_gain	1.0000
1:15626668:GATC:G	acceptor_gain	1.0000
1:15626799:G:GG	donor_gain	1.0000
1:15630322:CAGAC:C	acceptor_loss	1.0000
1:15630323:A:AG	acceptor_gain	1.0000
1:15630324:G:GG	acceptor_gain	1.0000
1:15630324:G:GT	acceptor_loss	1.0000
1:15630324:GACTT:G	acceptor_gain	1.0000
1:15630562:G:GC	donor_loss	1.0000
1:15630562:G:GG	donor_gain	1.0000
1:15630563:TAAG:T	donor_loss	1.0000
1:15633429:A:AG	acceptor_gain	1.0000
1:15633430:T:G	acceptor_gain	1.0000
1:15633434:T:TA	acceptor_gain	1.0000
1:15633435:GTAG:G	acceptor_loss	1.0000
1:15633436:TAGA:T	acceptor_gain	1.0000
1:15633437:A:AG	acceptor_gain	1.0000
1:15633437:AG:A	acceptor_loss	1.0000
1:15633438:G:GA	acceptor_gain	1.0000
1:15633438:GA:G	acceptor_gain	1.0000
1:15633438:GAGA:G	acceptor_gain	1.0000
1:15633438:GAGAA:G	acceptor_gain	1.0000

AlphaMissense

2603 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:15630511:T:C	L152P	1.000
1:15633542:G:C	Q203H	1.000
1:15633542:G:T	Q203H	1.000
1:15638338:G:C	A222P	1.000
1:15638339:C:A	A222D	1.000
1:15638362:T:C	F230L	1.000
1:15638363:T:G	F230C	1.000
1:15638364:T:A	F230L	1.000
1:15638364:T:G	F230L	1.000
1:15638378:T:C	M235T	1.000
1:15638379:G:A	M235I	1.000
1:15638379:G:C	M235I	1.000
1:15638379:G:T	M235I	1.000
1:15638381:T:A	L236H	1.000
1:15638381:T:C	L236P	1.000
1:15638383:T:G	Y237D	1.000
1:15638392:T:C	C240R	1.000
1:15638393:G:A	C240Y	1.000
1:15638394:C:G	C240W	1.000
1:15638420:C:A	A249D	1.000
1:15638422:T:C	F250L	1.000
1:15638423:T:C	F250S	1.000
1:15638423:T:G	F250C	1.000
1:15638424:T:A	F250L	1.000
1:15638424:T:G	F250L	1.000
1:15638426:T:A	V251D	1.000
1:15638428:G:A	D252N	1.000
1:15638428:G:C	D252H	1.000
1:15638429:A:C	D252A	1.000
1:15638429:A:G	D252G	1.000

dbSNP variants (sampled 300 via entrez): RS1000104427 (1:15634862 A>G), RS1000114925 (1:15653253 G>A), RS1000119115 (1:15617041 C>G), RS1000181848 (1:15633065 A>G), RS1000212771 (1:15630478 T>C), RS1000235591 (1:15632843 T>C), RS1000340036 (1:15651149 G>A), RS1000354464 (1:15627665 A>G), RS1000445948 (1:15624294 A>G), RS1000483957 (1:15621576 G>C), RS1000520418 (1:15663216 A>G), RS1000641473 (1:15648773 G>C), RS1000734015 (1:15658975 T>C), RS1000954659 (1:15662786 A>G), RS1001082077 (1:15643344 A>G)

Disease associations

OMIM: gene MIM:620871 | disease phenotypes: MIM:167800

GenCC curated gene-disease

Mondo (1): hereditary chronic pancreatitis (MONDO:0008185)

Orphanet (1): Autosomal dominant hereditary chronic pancreatitis (Orphanet:676)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST004860_117	Alcoholic chronic pancreatitis	3.000000e-08
GCST004860_134	Alcoholic chronic pancreatitis	1.000000e-06
GCST007269_9	Pulse pressure	2.000000e-10
GCST007565_187	Morning person	3.000000e-16
GCST007576_356	Chronotype	3.000000e-16
GCST007876_63	Estimated glomerular filtration rate	4.000000e-16
GCST012020_63	Serum metabolite levels	4.000000e-77

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0008328	chronotype measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C537262	Hereditary pancreatitis (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	increases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
pyrogallol 1,3-dimethyl ether	affects localization, increases expression, affects cotreatment	1
sodium arsenite	decreases expression	1
butyraldehyde	increases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
bisphenol S	increases expression	1
bisphenol AF	increases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Leflunomide	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Caffeine	increases phosphorylation	1
Dimethyl Sulfoxide	increases expression	1
Estradiol	increases expression	1
Furaldehyde	affects cotreatment, affects localization, decreases expression	1
Hydrogen Peroxide	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Methapyrilene	decreases methylation	1
Sodium Chloride	affects localization, decreases expression, increases expression, affects cotreatment	1
Theophylline	affects cotreatment, increases expression	1
Valproic Acid	increases expression	1
Sodium Selenite	decreases expression	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SK53	HAP1 DDI2 (-) 1	Cancer cell line	Male
CVCL_SK54	HAP1 DDI2 (-) 2	Cancer cell line	Male
CVCL_SK55	HAP1 DDI2 (-) 3	Cancer cell line	Male
CVCL_SK56	HAP1 DDI2 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

7 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00830557	Not specified	RECRUITING	Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
NCT02078245	Not specified	UNKNOWN	Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.
NCT02206360	Not specified	ACTIVE_NOT_RECRUITING	Pancreatic Cancer Early Detection Program
NCT02309632	Not specified	WITHDRAWN	Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
NCT04095195	Not specified	RECRUITING	Registry of Subjects at Risk of Pancreatic Cancer
NCT04743479	Not specified	RECRUITING	Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
NCT07413029	Not specified	RECRUITING	French National Cohort of Patients With PRSS1 Mutations